RhumbLine Advisers’s Radiopharm Theranostics RADX Stock Holding History

RhumbLine Advisers’s Portfolio RADX Stock Details RADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$315	Hold	195	–	–	﹤0.01%	3988
2026 Q2	$817	Buy	195 +74	+61%	+$329	﹤0.01%	4037
2026 Q1	$519	Buy	121 +115	+1,917%	+$562	﹤0.01%	4010
2025 Q4	$31	Buy	+6	New	+$32	﹤0.01%	4113

Other funds holding RADX

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

RhumbLine Advisers's RADX Position: Q3 2026 in Review

RhumbLine Advisers held its Radiopharm Theranostics (RADX) position steady in Q3 2026 at 195 shares worth $315. The position accounts for ﹤0.01% of the portfolio, ranked #3988.

RhumbLine Advisers first reported a position in RADX in Q4 2025 and has held it in 4 quarters since. The position peaked at $817 in Q2 2026. 3 funds tracked by Wall St. Rank hold RADX as of Q3 2026.

RhumbLine Advisers held 195 shares of Radiopharm Theranostics worth $315 as of Q3 2026.
RhumbLine Advisers left its Radiopharm Theranostics share count unchanged in Q3 2026.
Radiopharm Theranostics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3988 holding.
RhumbLine Advisers first reported a position in Radiopharm Theranostics in Q4 2025 and has held it in 4 quarters since.
RhumbLine Advisers's Radiopharm Theranostics position peaked at $817 in Q2 2026.
3 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.